GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Shiller PE Ratio

GenMark Diagnostics (GenMark Diagnostics) Shiller PE Ratio : (As of May. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GenMark Diagnostics Shiller PE Ratio Historical Data

The historical data trend for GenMark Diagnostics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GenMark Diagnostics Shiller PE Ratio Chart

GenMark Diagnostics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GenMark Diagnostics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GenMark Diagnostics's Shiller PE Ratio

For the Medical Devices subindustry, GenMark Diagnostics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMark Diagnostics's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GenMark Diagnostics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GenMark Diagnostics's Shiller PE Ratio falls into.



GenMark Diagnostics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GenMark Diagnostics's E10 for the quarter that ended in Dec. 2020 is calculated as:

For example, GenMark Diagnostics's adjusted earnings per share data for the three months ended in Dec. 2020 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=-0.05/109.8968*109.8968
=-0.050

Current CPI (Dec. 2020) = 109.8968.

GenMark Diagnostics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201103 -0.560 94.283 -0.653
201106 -0.390 95.235 -0.450
201109 -0.310 95.727 -0.356
201112 -0.250 95.213 -0.289
201203 -0.280 96.783 -0.318
201206 -0.260 96.819 -0.295
201209 -0.200 97.633 -0.225
201212 -0.130 96.871 -0.147
201303 -0.130 98.209 -0.145
201306 -0.250 98.518 -0.279
201309 -0.300 98.790 -0.334
201312 -0.260 98.326 -0.291
201403 -0.210 99.695 -0.231
201406 -0.270 100.560 -0.295
201409 -0.230 100.428 -0.252
201412 -0.210 99.070 -0.233
201503 -0.240 99.621 -0.265
201506 -0.290 100.684 -0.317
201509 -0.270 100.392 -0.296
201512 -0.210 99.792 -0.231
201603 -0.300 100.470 -0.328
201606 -0.300 101.688 -0.324
201609 -0.270 101.861 -0.291
201612 -0.270 101.863 -0.291
201703 -0.300 102.862 -0.321
201706 -0.370 103.349 -0.393
201709 -0.280 104.136 -0.295
201712 -0.260 104.011 -0.275
201803 -0.210 105.290 -0.219
201806 -0.300 106.317 -0.310
201809 -0.200 106.507 -0.206
201812 -0.210 105.998 -0.218
201903 -0.210 107.251 -0.215
201906 -0.230 108.070 -0.234
201909 -0.200 108.329 -0.203
201912 -0.170 108.420 -0.172
202003 -0.120 108.902 -0.121
202006 -0.070 108.767 -0.071
202009 -0.050 109.815 -0.050
202012 -0.050 109.897 -0.050

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GenMark Diagnostics  (NAS:GNMK) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


GenMark Diagnostics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GenMark Diagnostics (GenMark Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
5964 La Place Court, Carlsbad, CA, USA, 92008-8829
GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.
Executives
Tyler Jensen officer: SVP, Engineering and Tech Dev 5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw officer: VP, Assay Development 5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo officer: VP, Qual, Reg, & Clin Affairs 5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson officer: SVP, Corp. Accounts 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler officer: VP, Human Resources 5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins officer: SVP, Sales 5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director, officer: President & CEO 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier officer: SVP & General Counsel 5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell officer: SVP, Operations 5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff director DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox director 5964 LA PLACE COURT, CARLSBAD CA 92008